Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Navitoclax Monotherapy Mirrors Safety of Navitoclax/Ruxolitinib, But Falls Short in Efficacy in Myelofibrosis

June 16th 2022

Single-agent navitoclax achieved a manageable safety profile compared with navitoclax plus ruxolitinib in patients with myelofibrosis. However, efficacy results, specifically at 24 weeks of treatment, favored the combination over navitoclax monotherapy.

Myelofibrosis: Novel Combination Strategies

June 16th 2022

Focusing on novel combination strategies, experts review clinical trial data and consider where these regimens may fall in the myelofibrosis treatment armamentarium.

Novel Agents in the Pipeline for Myelofibrosis

June 16th 2022

A comprehensive review of novel agents currently under investigation with a potential role in the myelofibrosis treatment landscape.

Parsaclisib Plus Ruxolitinib Demonstrates Splenic Volume Reduction in Myelofibrosis Irrespective of Platelet Count

June 13th 2022

Add-on parsaclisib and ruxolitinib elicited promising spleen volume reduction in patients with myelofibrosis who experienced suboptimal response to ruxolitinib alone, regardless of baseline platelet count, according to findings from a subgroup analysis of a phase 2 study.

Pelabresib/Ruxolitinib Combo Demonstrates Promising Clinical Efficacy in Myelofibrosis

June 12th 2022

The combination of pelabresib and ruxolitinib produced responses that proved to be durable beyond week 24 in patients with myelofibrosis who experienced a suboptimal response to ruxolitinib and in those who were JAK inhibitor naïve.

Momelotinib Shows Superiority Over Danazol in Symptomatic and Anemic Myelofibrosis

June 11th 2022

Momelotinib demonstrated significant improvements in symptoms, spleen size, and anemia measures compared with danazol in patients with symptomatic and anemic myelofibrosis who previously received treatment with a JAK inhibitor.

Sintilimab Plus Decitabine Demonstrates 62% ORR in Untreated, Higher-Risk MDS

June 10th 2022

The combination of the PD-1 antibody sintilimab and decitabine elicited potent clinical activity and manageable safety with no grade 4 or 5 treatment-related adverse effects as frontline therapy in patients with higher-risk myelodysplastic syndrome, according to preliminary results from a phase 2 trial.

Myelofibrosis: Patient Monitoring and Triggers to Change Therapy

June 9th 2022

Expert perspectives on monitoring patients receiving therapy for myelofibrosis, with additional considerations for when it is appropriate to switch therapy.

Selection and Management of JAK Inhibitor Therapy in MF

June 9th 2022

Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.

Magrolimab Plus Azacitidine Elicits Manageable Anemia in HR-MDS

June 4th 2022

Magrolimab plus azacitidine, at priming and maintenance doses, enables manageable anemia in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, according to results from a prospective phase 1 study (NCT03248479).

Pacritinib Offers Safe and Tolerable Treatment Option for Patients With Myelofibrosis

June 4th 2022

Treatment with pacritinib demonstrated a comparable safety profile to best available therapies for the treatment of patients with myelofibrosis.

Myelofibrosis: Use of Fedratinib and Pacritinib Therapy

June 2nd 2022

Shared insight on the respective roles of fedratinib and pacritinib in patients diagnosed with myelofibrosis.

Use of Ruxolitinib in Myelofibrosis

June 2nd 2022

Expert perspectives on the role of ruxolitinib in patients who require systemic therapy for myelofibrosis.

Historical Approaches to the Management of MF

May 26th 2022

A brief review of the historical use of systemic therapy in patients who present with myelofibrosis.

Factors in Selecting Therapy for Myelofibrosis

May 26th 2022

Stephen Oh, MD, PhD, highlights the role of transplant in myelofibrosis before Ruben Mesa, MD, discusses factors in selecting systemic therapy.

FDA Places Partial Clinical Hold on Phase 1 Trial Evaluating FHD-286 in Relapsed/Refractory AML and MDS

May 20th 2022

The FDA has placed a partial clinical hold on a phase 1 trial investigating FHD-286 as a treatment for patients with relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome.

Myelofibrosis: Observation and Triggers to Initiate Therapy

May 19th 2022

Expert Pankit Vachhani, MD, breaks down best practices in observation and dictates when it is best to initiated therapy for myelofibrosis.

Risk Assessment and Staging of Myelofibrosis

May 19th 2022

Experts focus on how best to risk stratify and stage myelofibrosis using appropriate diagnostic tools and workup.

Addressing the Challenges in Diagnosing MF

May 12th 2022

Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.

Making a Differential Diagnosis of Myelofibrosis

May 12th 2022

Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.